US2018327863A1PendingUtilityA1

Arid1a and ppp2r1a mutations in cancer

Assignee: UNIV JOHNS HOPKINSPriority: Sep 3, 2010Filed: May 23, 2018Published: Nov 15, 2018
Est. expirySep 3, 2030(~4 yrs left)· nominal 20-yr term from priority
A61K 31/7088C12Q 1/6886G01N 33/5011A61K 31/711C12Q 2600/156
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Two genes, ARID1A (AT-rich interactive domain-containing protein 1A) and PPP2R1A (protein-phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer, diagnosing cancer, contributing to a diagnosis of cancer, confirming a diagnosis of cancer, identifying appropriate treatments for cancer, monitoring treatment of cancer, and evaluating treatment protocols for cancer, including ovarian clear cell carcinoma, breast cancer, colon cancer, gastric cancer, lung cancer, medulloblastoma, pancreatic cancer, and prostate cancer.

Claims

exact text as granted — not AI-modified
1 . A method of detecting cancer cells, comprising:
 (a) testing a biological sample of an individual to detect a mutation in an PPP2R1A GENE; AND   (b) identifying the biological sample as containing cancer cells if the PPP2R1A gene comprises the mutation,   Wherein the mutation is selected from the group consisting of 547C>G, 547C>T, and 544C>T, wherein the nucleotides are numbered by reference to SEQ ID NO:5.

Join the waitlist — get patent alerts

Track US2018327863A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.